NasdaqGS:MXCTLife Sciences
MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives
MaxCyte (NasdaqGS:MXCT) opened Q1 2026 with revenue of US$9.7 million and a basic EPS loss of US$0.04, while trailing 12 month figures show revenue of US$32.3 million and a basic EPS loss of US$0.37. The company has seen quarterly revenue move from US$10.4 million in Q1 2025 to US$9.7 million in Q1 2026, with net income moving from a loss of US$10.3 million to a loss of US$4.8 million over the same period. These figures frame the discussion for investors who are focused on how margins develop...